3,4-Diaminopyridine for myasthenia gravis

To assess the benefits and harms of 3,4-DAP for autoimmune MG, transient NMG and the CMS on 1) endurance, and 2) muscle strength, quality of life and Myasthenia Gravis Foundation of America (MGFA) status.

This is a protocol.

Health topics:

Cancer > Neurological > Paraneoplastic syndromes

Genetic disorders > Other genetic disorders

Neurology > Neuro-oncology > Paraneoplastic syndromes

Neurology > Neuromuscular junction disorders > Myasthenia gravis

Neurology > Peripheral neuropathy > Myasthenia gravis

facebook
twitter
whatsapp
email

Don't show again

What role do you identify with the most?

General public, patient, or care giver

Health practitioner

Researcher

Policy Maker

We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.